At the 3rd session of our education programme SIU360, we welcomed Steven Zimmer as our speaker in Oxford. Steven talked about the strategies one should be aware of when starting a new business, risks associated with start-ups and how to find the balance between one's passion in science and the market and much more! Here is the summary of what Steven told our participants on November 15.
Drug development is a very lengthy and expensive process. Are there ways to make the process easier and cheaper? Here we discuss the current trends in the pharma industry, if these trends are enough to achieve what's in the best interest of the industry, scientists, and most importantly, the patients, and what can be done to improve the situation in the future.
What awaits the biotech industry in the UK post-Brexit? Can the UK continue to thrive in biotech after the break-up from the EU is finalised? In the last instalment of our 'Brexit vs. Science' series we discuss the facts and speculations surrounding the most obvious questions on the effects of Brexit on the UK biotech industry.